Indian pharma sector to grow at 10-12 % during FY19-22: Icra


Indian pharmaceutical industry is expected to grow around 10-12 per cent between FY2019 and FY2022 while maintaining a stable outlook on the sector, ratings agency Icra said. It cited abating headwinds from pricing pressure in the US (which is the largest regulated market), stable growth for the Indian market driven by increasing healthcare spending and better accessibility as likely key growth drivers for the Indian pharma companies, coupled with comfortable balance sheet structure.


It, however, said increased cost related to regulatory compliances, especially for the US market, price controls across markets and mandatory genericisation for Indian market remained key risks.

“The domestic pharmaceutical industry has gained adequate scale and generic drug development capabilities over a decade of growth which will keep them in good stead to capture bigger opportunities, especially in the specialty/niche segments in the regulated market,” Icra said in a statement.

The FY2019-2022 compound annual growth rate (CAGR) is expected to be around 10-12 per cent for domestic pharmaceutical companies, it added.


Icra said growth from the US picked up in FY2019 to 12.1 percent after seeing a decline of 13.1 per cent in FY 2018.

“The growth was supported by higher market share for Indian players as several generic MNC players optimised product portfolios along with new product launches,” it added.

The pricing pressure led by consolidation of supply chain in the US market and faster abbreviated new drug application approvals is abating and is expected to remain in mid-single digit in FY2020 compared to low teens in FY2018.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top